Finch Therapeutics Group, Inc. (FNCHQ)
Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Finch Therapeutics Group, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 1.61M shares outstanding
USFinch Therapeutics Group, Inc. engages in the development of microbiome drugs.
Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms.
The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.
Leadership
Matthew Blischak
President, Secretary & Chief Executive Officer
James S. Sigler
Executive Vice President of CMC
Employees
--
Country
US
Sector
Healthcare
Website
finchtherapeutics.com
| Name | Shares | % | Source |
|---|---|---|---|
Chidozie Ugwumba · may incl. warrants· stale · filed Dec 2023 | 160.4K | 10.0% | 13G |
based on 1.61M shares outstanding
US30d Avg
--
60d Avg
3.94K
90d Avg
2.60K